1116691-26-9

Basic information

• Product Name: 3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid
• Synonyms: 3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid;3-BroMo-iMidazo[1,2-a]pyr...;IMidazo[1,2-a]pyridine-8-carboxylic acid, 3-broMo-
• CAS NO: 1116691-26-9
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.0415
• Mol File: 1116691-26-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.89±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.05±0.41(Predicted)
• CAS DataBase Reference: 3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid(1116691-26-9)
• EPA Substance Registry System: 3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid(1116691-26-9)

Safety Data

• Hazardous Substances Data: 1116691-26-9(Hazardous Substances Data)

Usage

General Description

3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid is a chemical compound with a complex structure. It falls under the category of bromides and imidazopyridines, which are often used in the development of various pharmaceuticals due to their diverse biological activities. The compound itself is significant in scientific research and is commonly used as a reagent, a substance that brings about a chemical reaction. This means it can be utilized in various chemical industry processes or in labs for research purposes. It is a solid substance and should be handled with protective clothing and eye protection. The exact properties such as melting point or density might differ depending on the specific conditions and additional substances it is combined with.

Upstream product

• 133427-08-4 H-imidazo[1,2-α]pyridine-8-carboxylic acid 
• 1234616-47-7 methyl 3-bromoimidazo[1,2-a]pyridine-8-carboxylate 

Downstream Products

• 1116690-47-1 (3-bromoimidazo[1,2-α]pyridin-8-yl)(4-(2,4-difluorophenethyl)piperazin-1-yl)methanone 

Relevant articles and documents

Structure-activity relationship studies for enhancer of zeste homologue 2 (EZH2) and enhancer of zeste homologue 1 (EZH1) inhibitors

EZH2 or EZH1 (enhancer of zeste homologue 2 or 1) is the catalytic subunit of polycomb repressive complex 2 (PRC2) that catalyzes methylation of histone H3 lysine 27 (H3K27). PRC2 hyperactivity and/or hypertrimethylation of H3K27 are associated with numerous human cancers, therefore inhibition of PRC2 complex has emerged as a promising therapeutic approach. Recent studies have shown that EZH2 and EZH1 are not functionally redundant and inhibition of both EZH2 and EZH1 is necessary to block the progression of certain cancers such as mixed-lineage leukemia (MLL)-rearranged leukemias. Despite the significant advances in discovery of EZH2 inhibitors, there has not been a systematic structure-activity relationship (SAR) study to investigate the selectivity between EZH2 and EZH1 inhibition. Here, we report our SAR studies that focus on modifications to various regions of the EZH2/1 inhibitor UNC1999 (5) to investigate the impact of the structural changes on EZH2 and EZH1 inhibition and selectivity.